NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
13 Novembro 2023 - 10:57AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced significant updates to the
NeuroStar software and TrakStar® Patient Data Management System, a
proprietary, HIPAA-compliant, patient management and outcomes
reporting system for NeuroStar providers. For TrakStar, this marks
the third update to the platform this year.
“The NeuroStar and TrakStar software updates are set to usher in
a new era of patient care and data management,” stated Cory
Anderson, SVP of R&D and Clinical. “These updates represent our
goal to support NeuroStar devices throughout their operational
lifespan and build a foundation for future improvements. We are
committed to ensuring that our NeuroStar technology and TrakStar
platform can aid practices in delivering the best possible outcomes
for patients struggling to find relief from the debilitating
symptoms of depression.”
NeuroStar’s innovative software update is set to redefine the
user experience for all legacy NeuroStar systems while maintaining
the original workflow. The enhancement includes a new user
interface and software platform, ensuring a uniform, seamless
experience across all devices.
In addition to the NeuroStar software update, TrakStar’s
software is upgraded to significantly enhance patient care and
practice management. The standout feature of this update is its
ability to proactively notify NeuroStar providers when patients
exhibit signs of relapse or experience changes in their mental
health post-NeuroStar transcranial magnetic stimulation (TMS)
treatment. These real-time notifications empower practices to
swiftly identify patients who may require a follow-up NeuroStar
treatment or clinical evaluation. Additional TrakStar updates
include improvements to the potential patient dashboard, allowing a
more streamlined process to identify patients ready for
consultation and review their clinical history of PHQ-10 surveys.
Moreover, improved outcomes reporting within TrakStar offers
practices versatile options for tracking individualized patient
progress.
“TrakStar’s capabilities have proven to be a valuable asset in
my practice,” expressed Dr. Geoffrey Grammer, Chief Medical Officer
at Greenbrook TMS Neuroheath Centers. “The ability to identify
patients who may benefit from retreatment with NeuroStar TMS
therapy is a significant and game-changing advancement in our
patient care protocols, ensuring that those in need are easily
identified and receive the appropriate attention and support they
deserve. NeuroStar continually demonstrates that they are committed
to best-in-class patient care and outcomes.”
The NeuroStar software will be rolled out in phases during the
4th quarter, starting today. Simultaneously, the TrakStar software
is now available to all customers. For more information about
NeuroStar Advanced Therapy, please visit neurostar.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
NeuroStar is FDA-cleared for adults with major depressive disorder
(MDD), as an adjunct for adults with obsessive-compulsive disorder
(OCD), and to decrease anxiety symptoms in adult patients with MDD
that may exhibit comorbid anxiety symptoms (anxious depression).
NeuroStar Advanced Therapy is the leading transcranial magnetic
stimulation (TMS) treatment for MDD in adults with over 5.9 million
treatments delivered. NeuroStar is backed by the largest clinical
data set of any TMS system for depression, including the world’s
largest depression Outcomes Registry. Neuronetics is
committed to transforming lives by offering an exceptional
treatment that produces extraordinary results. For safety and
prescribing information, www.neurostar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024